Novo Nordisk said yesterday that it’s licensed a new obesity drug from The United Laboratories, a Chinese drugmaker.

Novo Nordisk has acquired the global rights to China-based United Laboratories’ triple-agonist weight-loss and diabetes drug ...

Novo Nordisk (NVO) ended the recent trading session at $75.89, demonstrating a +1.47% swing from the preceding day's closing price. The stock outperformed the S&P 500, which registered a daily ...

The company’s groundbreaking GLP-1 receptor agonists have revolutionized the management of these chronic conditions, propelling Novo Nordisk to new heights in the pharmaceutical industry. As the ...

The company has a debt-to-equity ratio of 0.23, a current ratio of 2.50 and a quick ratio of 1.53. Hawkins, Inc. has a 1-year low of $69.92 and a 1-year high of $139.55. Hawkins (NASDAQ ...

To make matters worse, on March 10, 2025, Novo Nordisk reported its CagriSema Phase 3 REDEFINE 2 CagriSema late-stage study revealed just 13.7% weight loss versus 3.1% placebo in overweight type 2 ...

Novo Nordisk (NVO) stock was down more than 8% Monday morning after the Danish drugmaker shared new data on its next-generation GLP-1 drug, CagriSema. The drug, a mix of cagrilintide and ...

Shares of U.S. rival Eli Lilly, which makes weight-loss drug Mounjaro, briefly jumped higher after Novo Nordisk's update on Monday, but were trading down 1.2% by 11:34 a.m. in London. Markets have ...

No­vo Nordisk is con­sid­er­ing in­ves­ti­gat­ing its GLP-1 ther­a­pies in the treat­ment of ad­dic­tions, mir­ror­ing sim­i­lar com­ments made by its ma­jor in­cretin ri­val ...

(MENAFN- GlobeNewsWire - Nasdaq) Dublin, March 06, 2025 (GLOBE NEWSWIRE) -- The "Insulin Pens market Size by Segments ... For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free ...